Cargando…

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer

OBJECTIVES: This study aimed to evaluate the safety and immunogenicity of inactivated COVID-19 vaccines in patients with gastrointestinal cancer (GI) cancer. The role of memory B cells (MBCs) in the humoral response to COVID-19 vaccination was also investigated. METHODS: In this prospective observat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tong, Song, Rui, Wang, Jingjie, Zhang, Jianbo, Cai, Hongxing, He, Hongmei, Hu, Wei, Yu, Dajun, Wang, Chuanhu, Pan, Qingbo, Peng, Mingli, Ren, Hong, Zhu, Peng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9316719/ https://www.ncbi.nlm.nih.gov/pubmed/35905950 http://dx.doi.org/10.1016/j.ijid.2022.07.050

Ejemplares similares

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer
por: Song, Rui, et al.
Publicado: (2022)

Weakened humoral immune responses of inactivated SARS‐CoV‐2 vaccines in patients with solid tumors
por: Chen, Zhiwei, et al.
Publicado: (2022)

Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China
por: Han, Xiaoxu, et al.
Publicado: (2022)

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China
por: Yi, Yunyun, et al.
Publicado: (2023)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients
por: Yang, Lei, et al.
Publicado: (2023)

The safety and immunogenicity to inactivated COVID-19 vaccine in patients with hyperlipemia
por: Yang, Lei, et al.
Publicado: (2023)

Safety and immunogenicity of inactivated COVID-19 vaccine in patients with metabolic syndrome: A cross-sectional observational study
por: Guo, Qiao, et al.
Publicado: (2022)

Safety and immunogenicity of a modified Omicron-adapted inactivated vaccine in healthy adults: a randomized, double-blind, active-controlled Phase III clinical trial
por: Hu, Jialei, et al.
Publicado: (2023)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
por: Nurpeisova, Ainur, et al.
Publicado: (2022)

Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine
por: Hwa, Shi-Hsia, et al.
Publicado: (2013)

Safety and immunogenicity of an inactivated thimerosal‐free influenza vaccine in infants and children
por: Nolan, Terry, et al.
Publicado: (2009)

The Western Equine Encephalitis Lyophilized, Inactivated Vaccine: An Update on Safety and Immunogenicity
por: Keshtkar-Jahromi, Maryam, et al.
Publicado: (2020)

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys
por: Zhou, Jun, et al.
Publicado: (2005)

Humoral immune responses to inactivated COVID-19 vaccine up to 1 year in children with chronic hepatitis B infection
por: Zhou, Yingzhi, et al.
Publicado: (2023)

Safety, Immunogenicity and Duration of Immunity Elicited by an Inactivated Bovine Ephemeral Fever Vaccine
por: Aziz-Boaron, Orly, et al.
Publicado: (2013)

Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China
por: Mo, Zhaojun, et al.
Publicado: (2017)

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
por: Kandeil, Ahmed, et al.
Publicado: (2021)

Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants
por: Gao, Shuyu, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep
por: Matsiela, Matome Selina, et al.
Publicado: (2023)

Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study
por: Wang, Xiaoqi, et al.
Publicado: (2022)

Immunogenicity and Safety of One versus Two Doses of Quadrivalent Inactivated Influenza Vaccine (IIV4) in Vaccine-Unprimed Children and One Dose of IIV4 in Vaccine-Primed Children Aged 3–8 Years
por: Shi, Yunfeng, et al.
Publicado: (2023)

Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial
por: Zhu, Dandan, et al.
Publicado: (2022)

Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis
por: Kang, Liangyu, et al.
Publicado: (2022)

Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
por: Feng, Yanmeng, et al.
Publicado: (2021)

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children
por: Langley, Joanne M., et al.
Publicado: (2013)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus
por: So, Ho, et al.
Publicado: (2022)

Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against reindeer rabies
por: Matveeva, Irina, et al.
Publicado: (2022)

Immunogenicity of SARS inactivated vaccine in BALB/c mice
por: Xiong, Sheng, et al.
Publicado: (2004)

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial
por: Xia, ShengLi, et al.
Publicado: (2022)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Safety and immunogenicity of a delta inulin-adjuvanted inactivated Japanese encephalitis virus vaccine in pregnant mares and foals
por: Bielefeldt-Ohmann, Helle, et al.
Publicado: (2014)

Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2022)

Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection
por: Xiang, Tiandan, et al.
Publicado: (2021)

Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults
por: Beran, Jiří, et al.
Publicado: (2013)

The Safety and Immunogenicity of Trivalent Inactivated Influenza Vaccination: A Study of Maternal-Cord Blood Pairs in Taiwan
por: Lin, Shin-Yu, et al.
Publicado: (2013)

Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children
por: Chanthavanich, Pornthep, et al.
Publicado: (2018)

Safety and immunogenicity evaluation of inactivated whole-virus-SARS-COV-2 as emerging vaccine development in Egypt
por: Saleh, Amani A, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2e9grjj2tc40b14h050tc07n5n